200 - Protocol for Employee Exposure to Blood/Blood Products: Needlestick

and Mucous Membrane Contact

 

      A.    Definition of an exposure

 

           Any Santa Cruz County employee who is exposed to blood or blood products in any of  the following  ways should  report  immediately to his/her supervisor for possible  post-exposure evaluation:

 

            1.    A wound caused by a sharp object contaminated by blood or blood products;

 

            2.    A splash of blood or blood products onto an open wound or an area of dermatitis (skin rash); or

 

            3.   Contact of blood or other body fluids with mucous membranes such as the eyes, nose, or mouth.

 

      B.    Employee/Supervisor Response

 

            1.    The employee who has had a blood or blood product exposure in one of the above ways should immediately contact his/her supervisor.

 

            2.    The Supervisor's First Report/Incident Report or Employee Accident Report must be completed.

 

            3.    The supervisor will contact one of the following persons, listed in descending order of preference:  the Medical Director- Occupational Health at HSA, the Communicable Disease (CD) Nurse, or the CD Program Manager if the incident occurred during a weekday. If the exposure occurred at night, on a weekend or holiday, one of the above persons must be contacted within 48 hours. The purpose of this step is to substantiate significant exposure and proceed with post-exposure evaluation.

 

            4.    If the exposure occurs during a weekday, evaluation will be performed at the direction of one of the above named HSA Occupational Health or CD personnel. If the incident occurs after normal HSA hours, the supervisor will advise the employee regarding at which medical facility care should be initiated, with scheduled follow-up performed by the Medical Director - Occupational Health.

 

            5.      If the blood/blood product source person is known, voluntary testing of his/her blood should be requested and arranged by the employee's department.  If blood tests are performed on the source person for hepatitis, informed consent is encouraged. The Medical Director-Occupational Health or CD personnel can arrange for counseling. If blood tests are performed on the source person for HIV (the virus presumed to cause AIDS),pretest counseling and informed consent from the source person must be obtained prior to drawing a blood sample for testing. The employee’s department should perform HIV counseling for the source patient when appropriate, or referred to the HSA AIDS Program for counseling and testing. The Medical Director-occupational Health or CD personnel may request blood testing on the source person.

 

            6.    If the source person is in a detention setting, voluntary testing of his/her blood should be requested and arranged through the Detention Nurse Program Manager and/or the Detention Public Health Nurse. If the exposure is deemed significant on discussion between the employee and the Medical Director  - Occupational Health, mechanisms exist to obtain court-ordered mandatory HIV testing of refusing juveniles and adult inmates. The need for such testing must be discussed with the Detention Nurse Program Manager, Detention Medical Director, and/or the County Health Officer before the court-ordered process is pursued.

 

            7.  The exposed employee will be requested to provide a blood sample for baseline testing. The Medical Director-Occupational Health or CD personnel will request blood tests on the employee.

 

            8.    The employee's department will be billed for all tests.

 

      C.    Evaluation/Treatment Guidelines

 

           The major communicable diseases of concern after a blood/ blood product exposure are: tetanus, HIV Disease, and hepatitis B and Non-A, Non-B. If the exposure is felt to be significant by the medical care provider, the following disease- specific guidelines should be closely adhered to.

 

            TETANUS

 

           Employees who receive any scratch, cut, or puncture wound shall get an adult tetanus/diphtheria booster, if indicated, as per the guidelines of the American College of Surgeons.

 

            HIV   DISEASE

 

            1.    Employee/Supervisor Information

 

                The employee should be reassured as to the very low risk (less than 1%) of acquiring HIV Disease from exposure to the blood of an infected person or through a used needle. The importance of follow up and adherence to these guidelines should be stressed, however.

 

                The Medical Director - Occupational Health or CD personnel to a designated HSA HIV counselor, shall refer each exposed employee.

 

                The exposed employee should be encouraged to be tested for HIV at time of the exposure. The confidentiality of employee HIV testing will be ensured at all times.

 

            2.    Health Care Provider Information

 

                  The source person should be informed of the incident and have voluntary confidential HIV testing after pretest counseling is provided and informed consent is obtained. Written consent to release the test result to the exposed employee and to the Medical Director -Occupational Health, should also be obtained. This should be arranged by the employee's department and billed to that department. HSA clients and jail inmates shall, for the purposes of this protocol, be considered at high risk for HIV infection unless an accurate history is obtained from the source person and it is subsequently determined that the client falls into a low-risk category. In addition, a cut or puncture wound from any used needle, with no identifiable sources, shall be considered a high-risk exposure.

 

                The following guidelines are adapted from CDC recommendations for health care workers, and apply to other employee exposures (MMWR - August 21, 1987 and June 24, 1988).

 

                  a.      No further follow up of the exposed employee is needed if the source blood tests negative and the source is determined to be in a low-risk category. However, at the employee's request, the employee may be retested at 3 months.

 

                  b.    If the source person has AIDS, is positive for the HIV antibody, refuses the test, or is sero negative but in a high-risk group, the employee should be counseled regarding the risk of infection and evaluated clinically and serologically for evidence of HIV infection as soon as possible after exposure. The employee should be advised to report and seek medical evaluation for any acute febrile illness that occurs within 12 weeks of the exposure. Such an illness, particularly one characterized by a fever, rash, and/or lymphadenopathy, may be indicative of recent HIV infection.  If the employee elected to be tested for HIV and was initially negative, he/she should be retested at 6 weeks, 12 weeks, and 6 months post-exposure to determine if HIV transmission has occurred.  During the follow-up period, especially in the first 12 weeks after exposure, the exposed employee should follow recommendations for preventing transmission of HIV.

 

                  c.  appropriate counseling and education regarding HIV Disease should be provided to the employee. The employee may be referred to HSA CD personnel who can provide the counseling.

 

                  d.  Medical interventions, such as the prophylactic use of AZT following an exposure, are currently controversial and left to the discretion of the physician providing ongoing care to the exposed employee. Consultation on the prophylactic use of AZT may be obtained from the Medical Director Occupational Health.

 

 

            HEPATITIS B AND NON-A, NON-B

 

            1.    Employee/Supervisor Information

 

                     There are several types of viral hepatitis, but the two most important types transmitted by exposure to infected blood are hepatitis B and Non-A, Non-B. The risk of hepatitis B infection from a needle stick or splash onto mucous membranes is between 6 and 30% if the source person is infected and is similar for Non-A Non-B hepatitis. Post-exposure treatment may be effective in reducing this risk if done in a timely manner. A hepatitis B vaccine is available which may help prevent this infection in the exposed employee. If the source person can be identified, then it should be determined whether or not the source is at high risk for hepatitis B.

 

                     There is a blood test that can detect active hepatitis B, but there is currently no test for Non-A, Non-B.

 

            2.    Health Care Provider Information

 

                  a.  If the source person is known, informed consent should be obtained to perform testing for the hepatitis B surface antigen after it has been determined that the source is at high risk for hepatitis B surface antigen positivity.

 

                  b.    Employee exposure risk may be determined by risk category of the site of exposure or by history obtained from the source:

 

                        1.    Low Risk Category

 

                              a)     Children being seen at immunization  clinics are generally low risks.

 

                              b)    Otherwise,  to  qualify  as  a  low   risk source,  the  client  should  clearly  and reliably not fall into a high risk category as judged by the provider who is evaluating the exposure.

 

                        2.    High Risk Category

 

                              a)         Most HSA, Sheriff's Office, and detention facility clients should be considered high risks unless it can be established with reasonable certainty that the client does not fall into the high risk category.

 

                              b)         Hemodialysis patients, patients from institutions for  the  mentally  ill or retarded, Southeast Asians, IV drug users, gay males, hemophiliacs, or persons with a past history of "hepatitis" or with  signs or symptoms of hepatitis should be considered high risk individuals.

 

                              c)      If the source person cannot be identified, the exposure should  be considered a  high risk one.

 

 

                  C.           Depending on the exposure risk and the immunization status of the employee, one of the following treatment protocols should be closely followed:

 

                        1.      Hepatitis Non-A, Non-B: If the health care provider has reason to suspect exposure to Non- A, Non-B hepatitis, immune serum globulin  (ISG) should be administered as soon after significant exposure as possible.

 

                        2.    Hepatitis B

 

                        NOTE: Employees currently receiving the hepatitis B vaccination series and employees who have completed the vaccination series and have not yet had the adequacy of their anti-HBs  titer documented, should  not be considered immune.

 

                              a) Low risk source/exposed employee vaccinated - test exposed employee for anti-HBs unless an adequate* titer has been demonstrated within the last two years. If the level is adequate, no further action is required. If the level is inadequate, complete the series or give a booster dose as appropriate.

 

                              b)   Low  risk   source/exposed  employee   not vaccinated -  initiate hepatitis  vaccination series.

 

                              c)      High risk source/exposed employee vaccinated - test source blood for HBSAG and test exposed employee for anti-HBS titer. If the HBsAg status of the source blood cannot be determined within 72 hours of the exposure, treat  the exposed employee as if the source  blood is HBsAg  positive and initiate therapy immediately.

 

 

_______________________________________________________________________

EXPOSED EMPLOYEE ANTI-HBs ADEQUATE* EXPOSED EMPLOYEE ANTI-HBs INADEQUATE

 

SOURCE POSITIVE                              SOURCE NEGATIVE

 

No further action                            No further action

 

Give HBIG 0.6cc/kg                       Give booster dose of vaccine at different body site

Give booster dose of vaccine

 

 

* Adequate anti-HBs is greater than or equal to 10 SRU by RIA or positive by EIA.

_______________________________________________________________________

 

                              d)  High  risk  source/exposed  employee  not  vaccinated- test source  blood for  HBsAg. If the HBsAg status of the source blood cannot be determined within 72 hours of the exposure, treat the exposed employee as if the source blood is HBsAg positive and initiate therapy immediately.

 

                                    If the source blood is  HBsAg  positive, give the exposed  employee HBIG  0.06cc/kg and initiate the hepatitis vaccine  series at a different body site.

 

                                   If the source blood is  HBsAg  negative,  initiate the hepatitis vaccine series